Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forest Sees Two Potential Fibromyalgia Indications For Milnacipran

This article was originally published in The Pink Sheet Daily

Executive Summary

Forest has two potential indications for its fibromyalgia therapy milnacipran, President & Chief Operating Officers Ken Goodman said during the firm's July 19 investor call

You may also be interested in...



Forest Snaps Up SNRI, Builds Pipeline

Potential successor to Lexapro may be safer than stalled fibromyalgia drug milnacipran.

Forest Snaps Up SNRI, Builds Pipeline

Potential successor to Lexapro may be safer than stalled fibromyalgia drug milnacipran.

Forest/Cypress Fibromyalgia Treatment Milnacipran Aims To Take On Pfizer’s Lyrica With More Robust Data

Cypress Chief Business Officer tells the DAILY that use of a more stringent composite endpoint could provide advantage for milnacipran over Lyrica and other potential treatments.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS062578

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel